toyocamycin has been researched along with puromycin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Busch, H; Chan, PK; Yung, BY | 1 |
Bodeau, S; Choukroun, G; Descamps, V; François, C; Galmiche, A; Godin, C; Louandre, C; Nyga, R; Sauzay, C | 1 |
2 other study(ies) available for toyocamycin and puromycin
Article | Year |
---|---|
Translocation of nucleolar phosphoprotein B23 (37 kDa/pI 5.1) induced by selective inhibitors of ribosome synthesis.
Topics: Amanitins; Cell Nucleolus; Cycloheximide; Dactinomycin; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; HeLa Cells; Humans; Molecular Weight; Nuclear Proteins; Nucleophosmin; Puromycin; Ribonucleoproteins; Ribosomes; Toyocamycin | 1985 |
Targeting the Unfolded Protein Response as a Potential Therapeutic Strategy in Renal Carcinoma Cells Exposed to Cyclosporine A.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cyclosporine; Endoribonucleases; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Immunosuppressive Agents; Kidney Neoplasms; Oxygen; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Puromycin; RNA Interference; RNA, Small Interfering; Toyocamycin; Unfolded Protein Response; Vascular Endothelial Growth Factor A | 2017 |